company background image
300199 logo

Hybio Pharmaceutical XSEC:300199 Stock Report

Last Price

CN¥10.81

Market Cap

CN¥9.5b

7D

2.0%

1Y

-7.0%

Updated

14 Jun, 2024

Data

Company Financials

Hybio Pharmaceutical Co., Ltd.

XSEC:300199 Stock Report

Market Cap: CN¥9.5b

300199 Stock Overview

Engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally.

300199 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rewards

Risk Analysis


Hybio Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hybio Pharmaceutical
Historical stock prices
Current Share PriceCN¥10.81
52 Week HighCN¥20.88
52 Week LowCN¥8.66
Beta0.57
1 Month Change-8.31%
3 Month Change-20.57%
1 Year Change-6.97%
3 Year Change95.13%
5 Year Change15.00%
Change since IPO-43.34%

Recent News & Updates

Recent updates

Shareholder Returns

300199CN PharmaceuticalsCN Market
7D2.0%-1.1%0.06%
1Y-7.0%-12.5%-16.1%

Return vs Industry: 300199 exceeded the CN Pharmaceuticals industry which returned -11.9% over the past year.

Return vs Market: 300199 exceeded the CN Market which returned -15.5% over the past year.

Price Volatility

Is 300199's price volatile compared to industry and market?
300199 volatility
300199 Average Weekly Movement8.0%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.2%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 300199's share price has been volatile over the past 3 months.

Volatility Over Time: 300199's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998895n/awww.hybio.com.cn

Hybio Pharmaceutical Co., Ltd. engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally. It offers liraglutide, semaglutide, and exenatide for diabetes; terlipressin, desmopressin, and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix, and atosiban for obstetrics and gynecology; customized peptides; working standards for the peptide APIs and related impurities; peptide CRO; and CDMO services, which include peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory, and dossier support. The company was founded in 1998 and is based in Wuhan, China.

Hybio Pharmaceutical Co., Ltd. Fundamentals Summary

How do Hybio Pharmaceutical's earnings and revenue compare to its market cap?
300199 fundamental statistics
Market capCN¥9.55b
Earnings (TTM)-CN¥546.58m
Revenue (TTM)CN¥405.42m

23.6x

P/S Ratio

-17.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300199 income statement (TTM)
RevenueCN¥405.42m
Cost of RevenueCN¥268.34m
Gross ProfitCN¥137.08m
Other ExpensesCN¥683.67m
Earnings-CN¥546.58m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.62
Gross Margin33.81%
Net Profit Margin-134.82%
Debt/Equity Ratio220.2%

How did 300199 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.